301 related articles for article (PubMed ID: 33433598)
1. Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer.
Patel KK; Stein S; Lacy J; O'Hara M; Huntington SF
JAMA Netw Open; 2021 Jan; 4(1):e2033441. PubMed ID: 33433598
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA.
Li S; Hu H; Ding D; Zhu Y; Huang J
Adv Ther; 2021 Mar; 38(3):1650-1659. PubMed ID: 33569738
[TBL] [Abstract][Full Text] [Related]
3. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated
Tabernero J; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Elez E; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
J Clin Oncol; 2021 Feb; 39(4):273-284. PubMed ID: 33503393
[TBL] [Abstract][Full Text] [Related]
4. Encorafenib, Binimetinib, and Cetuximab in
Kopetz S; Grothey A; Yaeger R; Van Cutsem E; Desai J; Yoshino T; Wasan H; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Pfeiffer P; Orlov S; Lonardi S; Elez E; Kim TW; Schellens JHM; Guo C; Krishnan A; Dekervel J; Morris V; Calvo Ferrandiz A; Tarpgaard LS; Braun M; Gollerkeri A; Keir C; Maharry K; Pickard M; Christy-Bittel J; Anderson L; Sandor V; Tabernero J
N Engl J Med; 2019 Oct; 381(17):1632-1643. PubMed ID: 31566309
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial.
Trouiller JB; Macabeo B; Poll A; Howard D; Buckland A; Sivignon M; Clay E; Malka D; Samalin E; Toumi M; Laramée P
BMJ Open; 2022 Nov; 12(11):e063700. PubMed ID: 36410812
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
[TBL] [Abstract][Full Text] [Related]
8. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With
Van Cutsem E; Huijberts S; Grothey A; Yaeger R; Cuyle PJ; Elez E; Fakih M; Montagut C; Peeters M; Yoshino T; Wasan H; Desai J; Ciardiello F; Gollerkeri A; Christy-Bittel J; Maharry K; Sandor V; Schellens JHM; Kopetz S; Tabernero J
J Clin Oncol; 2019 Jun; 37(17):1460-1469. PubMed ID: 30892987
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial.
Wang H; Huang L; Gao P; Zhu Z; Ye W; Ding H; Fang L
BMJ Open; 2020 Feb; 10(2):e030738. PubMed ID: 32051297
[TBL] [Abstract][Full Text] [Related]
10. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
11. Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
Shi Y; Wan X; Tan C; Li J; Peng L
Adv Ther; 2020 Feb; 37(2):847-859. PubMed ID: 31902066
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
[TBL] [Abstract][Full Text] [Related]
14. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
J Clin Oncol; 2015 Apr; 33(10):1112-8. PubMed ID: 25691669
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer.
Han J; Xiao D; Tan C; Zeng X; Hu H; Zeng S; Jiang Q; She L; Yao L; Li L; Tang L; Ma J; Huang J; Shen L
Cancer Control; 2020; 27(1):1073274820902271. PubMed ID: 32107929
[TBL] [Abstract][Full Text] [Related]
16. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of
Stintzing S; van Oostrum I; Pescott CP; Ronga P; Heeg B; Heinemann V
J Med Econ; 2020 May; 23(5):448-455. PubMed ID: 31903807
[No Abstract] [Full Text] [Related]
18. Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation.
Al-Salama ZT
Drugs; 2021 May; 81(7):849-856. PubMed ID: 33914242
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer.
Giuliani J; Mantoan B; Bonetti A
J Oncol Pharm Pract; 2022 Jan; 28(1):199-202. PubMed ID: 34581610
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
